s are
based on management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but not limited
to, Transcept product candidates may have unexpected adverse side effects or
inadequate therapeutic efficacy; positive results in clinical trials may not
be sufficient to obtain FDA approval; physician or patient reluctance to use
Intermezzo(R), if approved; potential alternative therapies; maintaining
adequate patent or trade secret protection without violating the intellectual
property rights of others; and other difficulties or delays in, clinical
development, obtaining regulatory approval, market acceptance and
commercialization of Transcept product candidates.
Contacts:
Transcept Pharmaceuticals, Inc. The Ruth Group
Michael Gill Investors / Media
Director of Communications Stephanie Carrington / Jason Rando
(510) 215-3575 (646) 536-7017 / 7025
mgill@transcept.com scarrington@theruthgroup.com
jrando@theruthgroup.com
'/>"/>SOURCE Transcept Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference2.
Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference3.
Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston4.
Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference5.
Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference6.
Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference7.
Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference8.
Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference9.
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum10.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference11.
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing